- Home
- CASI vs OKYO Comparison
CASI vs OKYO Comparison
Compare CASI & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- OKYO
- Stock Information
- Founded
- CASI 1991
- OKYO 2007
- Country
- CASI China
- OKYO United Kingdom
- Employees
- CASI N/A
- OKYO N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CASI Health Care
- OKYO Health Care
- Exchange
- CASI Nasdaq
- OKYO Nasdaq
- Market Cap
- CASI 35.0M
- OKYO 37.0M
- IPO Year
- CASI 1996
- OKYO 2022
- Fundamental
- Price
- CASI $2.21
- OKYO $1.39
- Analyst Decision
- CASI Strong Buy
- OKYO Strong Buy
- Analyst Count
- CASI 1
- OKYO 1
- Target Price
- CASI $6.00
- OKYO $7.00
- AVG Volume (30 Days)
- CASI 8.1K
- OKYO 132.2K
- Earning Date
- CASI 03-27-2025
- OKYO 03-25-2025
- Dividend Yield
- CASI N/A
- OKYO N/A
- EPS Growth
- CASI N/A
- OKYO N/A
- EPS
- CASI N/A
- OKYO N/A
- Revenue
- CASI $22,055,000.00
- OKYO N/A
- Revenue This Year
- CASI N/A
- OKYO N/A
- Revenue Next Year
- CASI $134.79
- OKYO N/A
- P/E Ratio
- CASI N/A
- OKYO N/A
- Revenue Growth
- CASI N/A
- OKYO N/A
- 52 Week Low
- CASI $2.04
- OKYO $0.81
- 52 Week High
- CASI $7.67
- OKYO $1.90
- Technical
- Relative Strength Index (RSI)
- CASI 35.91
- OKYO 68.12
- Support Level
- CASI $2.15
- OKYO $1.14
- Resistance Level
- CASI $2.49
- OKYO $1.45
- Average True Range (ATR)
- CASI 0.15
- OKYO 0.09
- MACD
- CASI 0.00
- OKYO 0.02
- Stochastic Oscillator
- CASI 35.42
- OKYO 84.21
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.